Nature Medicine11, 615 - 622 (2005)
Published online: 8 May 2005; | doi:10.1038/nm1244
Delay of HIV-1 rebound after cessation of antiretroviral therapy through passive transfer of human neutralizing antibodies
Alexandra Trkola1, Herbert Kuster1, Peter Rusert1, Beda Joos1, Marek Fischer1, Christine Leemann1, Amapola Manrique1, Michael Huber1, Manuela Rehr2, Annette Oxenius2, Rainer Weber1, Gabriela Stiegler3, Brigitta Vcelar3, Hermann Katinger3, Leonardo Aceto1
& Huldrych F Günthard1
1
Division of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich, Switzerland, Ramistrasse 100, 8091
Zurich, Switzerland.
2
Institute for Microbiology, ETH Hönggerberg, HCI 4 Wolfgang-Pauli-Strasse
8093
Zurich, Switzerland.
To determine the protective potential of the humoral immune response against HIV-1 in vivo we evaluated the potency of three neutralizing antibodies (2G12, 2F5 and 4E10) in suppressing viral rebound in six acutely and eight chronically HIV-1−infected individuals undergoing interruption of antiretroviral treatment (ART). Only two of eight chronically infected individuals showed evidence of a delay in viral rebound during the passive immunization. Rebound in antibody-treated acutely infected individuals upon cessation of ART was substantially later than in a control group of 12 individuals with acute infection. Escape mutant analysis showed that the activity of 2G12 was crucial for the in vivo effect of the neutralizing antibody cocktail. By providing further direct evidence of the potency, breadth and titers of neutralizing antibodies that are required for in vivo activity, these data underline both the potential and the limits of humoral immunity in controlling HIV-1 infection.
MORE ARTICLES LIKE THIS
These links to content published by NPG are automatically generated.
